ABBV — AbbVie Inc.
$295.03
+$0.58 (+0.20%)
AbbVie Inc., a research-based biopharmaceutical company, engages in the research and development, manufacturing, commercializing, and sale of medicines and therapies worldwide. The company offers Skyrizi to treat autoimmune diseases; Rinvoq to treat inflammatory diseases; Imbruvica for the treatment of adult patients with blood cancers; Venclexta to treat blood cancers; Elahere to treat various cancer; and Epkinly to treat lymphoma; and Emrelis for the treatment of lung cancer.
Market Cap
$521.50B
Forward P/E
18.2x
52-Week Range
N/A
ABBV Price History
Revenue vs. Net Income
$61.2B
Revenue · FY2025
Annual. Net margin is shown under each year.
Free Cash Flow
$17.8B
FCF · FY2025
Annual. FCF margin is shown under each year.
Return on Capital Employed (ROCE)
10.5%
ROCE · FY2025
Annual. Green above 0%, red below. Dashed line marks the 15% compounder threshold.
Total Assets vs. Total Liabilities
1.0x
Assets ÷ liabilities · FY2025
Annual. What the company owns against what it owes. Assets ÷ liabilities is shown under each year.
CapEx as % of Revenue
2.0%
CapEx · FY2025
Annual. Green at or under the 5% maximum target, red above it.
Shares Outstanding
+0.0%
Net buyback · FY2025
Annual diluted shares. Under each year: the change on the previous year (green = buyback, amber = dilution).
